| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $131,136 | 9 | 100 |
Sells | $0 | 0 | 0 |
| Equels Thomas K | CEO & President | 6 | $76,093 | 0 | $0 | $76,093 |
| KELLNER TED D | director | 1 | $50,000 | 0 | $0 | $50,000 |
| MITCHELL WILLIAM M | director | 1 | $5,000 | 0 | $0 | $5,000 |
| Rodino Peter W III | COO, Secretary, Gen. Counsel | 1 | $44 | 0 | $0 | $44 |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Over the last 12 months, insiders at AIM ImmunoTech Inc. have bought $131,136 and sold $0 worth of AIM ImmunoTech Inc. stock.
On average, over the past 5 years, insiders at AIM ImmunoTech Inc. have bought $108,865 and sold $884 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Equels Thomas K (CEO & President) — $76,093. KELLNER TED D (director) — $50,000. MITCHELL WILLIAM M (director) — $5,000.
The last purchase of 107 shares for transaction amount of $824 was made by Equels Thomas K (CEO & President) on 2025‑06‑13.
| 2025-06-13 | Equels Thomas K | CEO & President | 107 0.0097% | $7.70 | $824 | -61.64% | ||
| 2025-06-12 | Equels Thomas K | CEO & President | 103 0.0105% | $8.70 | $896 | -69.33% | ||
| 2025-04-11 | Equels Thomas K | CEO & President | 1.97M 0.5876% | $0.03 | $50,000 | -11.83% | ||
| 2025-04-11 | KELLNER TED D | director | 1.97M 0.5876% | $0.03 | $50,000 | -11.83% | ||
| 2025-04-11 | MITCHELL WILLIAM M | director | 196,851 0.0588% | $0.03 | $5,000 | -11.83% | ||
| 2025-04-04 | Equels Thomas K | CEO & President | 41,000 0.0304% | $0.06 | $2,583 | -70.56% | ||
| 2025-04-04 | Rodino Peter W III | COO, Secretary, Gen. Counsel | 500 0.0005% | $0.09 | $44 | -70.56% | ||
| 2025-03-05 | Equels Thomas K | CEO & President | 50,000 0.0738% | $0.13 | $6,730 | -78.92% | ||
| 2025-03-04 | Equels Thomas K | CEO & President | 127,334 0.1794% | $0.12 | $15,060 | -77.17% | ||
| 2024-12-19 | Sale | MITCHELL WILLIAM M | director | 4,580 0.0071% | $0.19 | $884 | -62.63% | |
| 2024-12-18 | Equels Thomas K | CEO & President | 22,727 0.035% | $0.21 | $4,682 | -62.00% | ||
| 2024-12-02 | APPELROUTH STEWART | director | 11,112 0.0168% | $0.21 | $2,356 | -61.86% | ||
| 2024-11-21 | Equels Thomas K | CEO & President | 20,000 0.0331% | $0.21 | $4,240 | -58.48% | ||
| 2024-11-20 | Equels Thomas K | CEO & President | 145,110 0.2237% | $0.19 | $27,915 | -56.00% | ||
| 2024-11-20 | APPELROUTH STEWART | director | 81,953 0.1267% | $0.19 | $15,817 | -56.00% | ||
| 2024-09-16 | Equels Thomas K | CEO & President | 5,000 0.0089% | $0.30 | $1,515 | -60.00% | ||
| 2024-09-13 | Equels Thomas K | CEO & President | 20,000 0.0363% | $0.31 | $6,160 | -56.67% | ||
| 2024-05-06 | Equels Thomas K | CEO & President | 61,729 0.117% | $0.41 | $25,000 | -40.48% | ||
| 2024-05-06 | Rodino Peter W III | COO, Secretary, Gen. Counsel | 30,865 0.0585% | $0.41 | $12,500 | -40.48% | ||
| 2024-03-21 | BRYAN NANCY | director | 38,462 0.0806% | $0.39 | $15,000 | -28.95% |
| KELLNER TED D | director | 1969504 66.9531% | $2.35M | 1 | 0 | |
| MITCHELL WILLIAM M | director | 521723 17.7359% | $623,458.99 | 3 | 1 | |
| Rodino Peter W III | COO, Secretary, Gen. Counsel | 401762 13.6579% | $480,105.59 | 6 | 0 | <0.0001% |
| Equels Thomas K | CEO & President | 38885 1.3219% | $46,467.58 | 49 | 0 | <0.0001% |
| CARTER WILLIAM A | CEO | 1225585 41.6636% | $1.46M | 9 | 2 | |
| APPELROUTH STEWART | director | 355509 12.0855% | $424,833.26 | 10 | 0 | <0.0001% |
| Bernhardt Charles Thomas III | Chief Financial Officer | 265214 9.0159% | $316,930.73 | 2 | 1 | |
| Lander Russel J | VP of Process/QualityAssurance | 207983 7.0704% | $248,539.69 | 4 | 0 | |
| SPENCE STEVEN D | director | 167870 5.7067% | $200,604.65 | 6 | 0 | |
| PIANI RICHARD | director | 102861 3.4967% | $122,918.90 | 2 | 0 | |
| ETHERIDGE RANSOM | director | 94430 3.2101% | $112,843.85 | 1 | 0 | |
| PASCALE ADAM | CFO | 59648 2.0277% | $71,279.36 | 3 | 0 | |
| BRYAN NANCY | director | 38462 1.3075% | $45,962.09 | 1 | 0 | <0.0001% |
| SPRINGATE WAYNE S | Sr. VP of Operations | 8672 0.2948% | $10,363.04 | 6 | 1 | |
| PETERSON ROBERT E | Chief Financial Officer | 8000 0.272% | $9,560.00 | 1 | 0 | |
| STRAYER DAVID R | Chief Science/Medical Officer | 5420 0.1843% | $6,476.90 | 10 | 2 | |
| Bonelli Anthony | President & COO | 2500 0.085% | $2,987.50 | 1 | 0 | |
| Dickey Robert IV | Senior Vice President | 2500 0.085% | $2,987.50 | 1 | 0 |
$1,138,733 | 28 | -4.94% | $3.94M | |
AIM ImmunoTech Inc. (AIM) | $337,688 | 19 | -33.30% | $3.52M |
$8,079,884 | 14 | -43.20% | $2.96M | |
$82,890 | 11 | -16.74% | $3.2M | |
$105,917 | 11 | -28.06% | $3.49M | |
$126,023 | 10 | -66.17% | $3.66M | |
$18,269 | 10 | -21.15% | $2.95M | |
$90,087 | 9 | 20.06% | $3.54M | |
$8,971,546 | 8 | 6.18% | $5.14M | |
$245,000 | 7 | -62.00% | $4.36M | |
$70,828 | 6 | -57.96% | $2.01M | |
$726,438 | 4 | -72.85% | $2.04M | |
$553,551 | 4 | -74.30% | $1.29M | |
$149,778 | 4 | -45.16% | $4.75M | |
$4,423 | 2 | 3.27% | $5.42M | |
$9,963 | 1 | -14.25% | $3.69M | |
$19,863 | 1 | 144.27% | $1.44M | |
$37,000 | 1 | 79.42% | $3.52M | |
$1,049,630 | 1 | -74.91% | $1.48M |
| Increased Positions | 8 | +66.67% | 106,118 | +874.62% |
| Decreased Positions | 3 | -25% | 10,892 | -89.77% |
| New Positions | 5 | New | 105,990 | New |
| Sold Out Positions | 2 | Sold Out | 10,014 | Sold Out |
| Total Postitions | 17 | +41.67% | 107,359 | +784.85% |